Drug Interaction:
Antacids, anticoagulants, cimetidine, ranitidine, digoxin, arsenide,
Sulphonlureas such as glibencamide,
Indomethicin, other NSAIDs,
Lithium, tripotassium, dicitro bismuthate
Warfarin,
ACE inhibitors, methotrexate,cyclosporine,
Phenytoin, amiodarone, miconazole, rifampicin
Indication:
LIST OF DRUGS DURING 2007
Sr.No- 71
Name of the Drug- Lornoxicam tablet 4mg/8mg Pharmacological Classification- For Osteoarthiritis rheumatoid arthiritis
Date of Approval- 21-05-07
Approved by U.S.FDA on 30-12-2007 (Ref- FDA approved List- 2007)
LIST OF DRUGS DURING 2007
Sr.No- 186
Name of the Drug- Lornoxicam tablet 8mg/2ml
Pharmacological Classification- For Short-term treatment of mild to moderate
pain,when oral administration is inappropiate
(ie.after dental surgery)
Date of Approval- 12-11-07
Approved by U.S.FDA on 30-12-2007 (Ref- FDA approved List- 2007)
Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
1.Lornoxicam 12mg SR 26-06-2009
(Addl.Stgth.)
Same as approved
2.Lornoxicam 4mg 13-09-2010
+ Eperisone 50mg tablet
For the improvement of myotonic conditions caused by neck shoulder
arm syndrome, scapulumeral periarthiritis and low back pain in adult
patients only
3.Lornoxicam 4mg 05-02-2009
+ Paracetamol 500mg
Film coated tablets
For the short term use in acute painful & inflammatory conditions in
adults
4.Lornoxicam 4mg/4mg 12-02-2010
+ Thiocolchicoside 4mg/8mg tablets
For the treatment of patients with acute painful musculoskeletal
conditions
5.Lornoxicam 8mg/2ml injection 12-11-2007
For short term treatment of mild to moderate pain, when oral
administration is inappropiate (after dental surgery)
6.Lornoxicam 8mg/8mg 23-03-2010
+ Thiocolchicoside 4mg/8mg tablets
(Addl.Higher stgth.)
Same as approved
7.Lornoxicam ER tablet 8mg 11-12-2009
(Addl.Stgth.)
Same as approved
8.Lornoxicam SR tablets 16mg 25-04-2009
For the symptomatic treatment of pain and inflammation in patients
of osteoarthiritis and rheumatoid arthiritis
9. Lornoxicam 4mg/8mg tablet 21-05-2007
For osteoarthiritis rheumatoid arthiritis
FIXED DOSE COMBINATIONS APPROVED BY DCG(I)
FROM JANUARY 1961 TILL NOVEMBER 2014
Name of Drug Indication Date of Approval
Lornoxicam 8mg + 14-05-2009
Paracetamol 500mg tablet
For the short term use in acute painful & inflammatory
conditions in adults
Acute pain and osteoarthiritis
Adverse Reaction:
Headache,GI disturbances such diarrhea, constipation, nausea,
Vomiting or abdominal pain, flatulence
Dysphagia, dry mouth, stomatitis
GORD, oesophagitis, rectal bleeding,
Ecchymoses, debility depression,
Visual disturbances, dyspepsia
Palpitations, dizziness, leg cramps,
Tinnitus, anaemia, altered taste
Oedema, alopecia, weight changes,
Itching, irritations, redness and rash
Inctreased sweating,
Ulceration or bleeding of the stomach or intestines
Thrombocytopenia. increase in liver enzyme
Contra-Indications:
Active peptic ulcer
Allergy to aspirin or other medicines in this class.
Patients under 18 years years
History of bronchospasm or urticaria orrhinitis or angioedema following admin. of asoirin or NSAIDs
Severely impaired kidney function, cardiac failure
Pregnancy
Lactation
Dosages/ Overdosage Etc:
Indication
Acute pain and osteoarthiritis
Dosage-
Pain relief- adult- 8 -16mg daily max 24mg daily
Osteoporosis- adult - 12mg daily in 2 -3 divided doses up to 16mg daily if needed
Parentral - pain relief - adult - 8mg once or bid by im /iv inj max - 24mg daily
Pharmacology/ Pharmacokinetics:
Pharmacodynamics
Analgesic and anti-inflammatory activity of Lornoxicam is due to its inhibitory action on postagladin synthesis via inhibition of cyclo-oxygenase COX activity. Unlike some NSAIDs however, lomoxicam does not inhibit 5- lipoxy-genase ativity and thus does not inhibit leukotriene synthesis or shunt arachionic acid to the 5- lipogenase pathway.
Pharmacokinetics-
Lornoxicam is rapidly and completely absorbed after oral administration reaching peak plasma concentrations of 270ug/L within 2.5 hours after a 4mg dose. The absorption of Lornoxcam is delayed and marginally reduced 20% in the presence of food.
The bioavailability is essentially 100%. It has an elimination half life of 4 hours, independent of dose Metabolised completely and approximately 1/3 rd is eliminated via the kidneys and 2/3ed via the liver, Its pharmacokinetics is similar in elderly and young subjects
Interaction with Food:
The absorption of Lornoxcam is delayed and marginally reduced 20% in the presence of food.
Pregnancy and lactation:
Contraindicated for use during pregnancy and lactation
Observe caution if required to be administered
Manufacturer Details